pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,380 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • STAT+: Europe will accelerate its review of RevMed’s drug
    Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout
    STAT · 17d ago↗ source
  • STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
    Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.
    STAT · 17d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
    The FDA approved a kidney disease drug from Vera Therapeutics called Trutakna, to treat IgA nephropathy
    STAT · 17d ago
← prev
page 14 of 56
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • Another big premium hike on the horizon
    FDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Rounds
    STAT · 17d ago↗ source
  • Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnerships
    Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to Astr…
    Endpoints · 17d ago↗ source
  • Satellos gives early look at Duchenne pill in adults ahead of key data in children
    Satellos Bioscience is building its case for a Duchenne muscular dystrophy pill with data in adult patients ahead of a potentially pivotal readout in children later this year. The Canadian biotec…
    Endpoints · 17d ago↗ source
  • Opinion: STAT+: What’s the right role for AI in dementia care?
    Three tricky questions about using AI in dementia care.
    STAT · 17d ago↗ source
  • Opinion: The AI licensure debate is missing the point of licensure
    “AI will reshape medicine. The physicians who answer for the outcome must lead the way it enters patient care," write Afnan R. Tariq and Ami Bhatt.
    STAT · 17d ago↗ source
  • Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
    The newly approved over-the-counter CGM offers a new approach to tackling childhood obesity but also raises a host of questions.
    STAT · 17d ago↗ source
  • STAT+: Trump administration pursues more durable changes to science policy after setbacks in court
    The White House has proposed sweeping changes to the bedrock regulation undergirding all federal contracts, empowering the executive branch to direct research, terminate grants, and external scient…
    STAT · 17d ago↗ source
  • Vertex's Crinetics deal points to big ambitions for cystic fibrosis leader
    Vertex Pharmaceuticals' $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry. Long a biotech s…
    Endpoints · 18d ago↗ source
  • Tampa General kicks off legal fight over Lilly's 340B restrictions
    Tampa General Hospital sued Eli Lilly for halting its 340B discounts, kicking off a broader fight over whether pharmaceutical companies can condition drug discounts on new claims data requirements.…
    Endpoints · 18d ago↗ source
  • Vera's IgAN approval kicks off competition with Otsuka
    Vera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys. The drug will be marketed as Trutakna for immunoglobu…
    Endpoints · 18d ago↗ source
  • STAT+: FDA approves Vera Therapeutics kidney disease treatment
    The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
    STAT · 18d ago↗ source
  • STAT+: The crumbling employer-based health insurance system
    Today's D.C. Diagnosis newsletter covers maintaining diversity in drug trials and troubling trends in employer-based health insurance.
    STAT · 18d ago↗ source
  • Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
    Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…
    Endpoints · 18d ago↗ source
  • Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
    The GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety pro…
    Endpoints · 18d ago↗ source
  • STAT+: Compass says depression drug has long-lasting benefits
    Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
    STAT · 18d ago↗ source
  • STAT+: America’s employer health insurance is decaying
    STAT's Bob Herman examines the under-the-radar crisis brewing in employer-based health insurance.
    STAT · 18d ago↗ source
  • Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half
    Biopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $1…
    Endpoints · 18d ago↗ source
  • MeiraGTx strikes royalty deal; Fore's 2023 Series D continues
    Plus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...
    Endpoints · 18d ago↗ source
  • STAT+: ‘Secret shopper’ study probes GLP-1 telehealth sites
    In this edition of STAT Health Tech: A 'secret shopper' study of telehealth sites prescribing GLP-1s, news about Epic, Anthropic, and brain implants.
    STAT · 18d ago↗ source
  • Conquering Medicare's ACCESS program
    There was so much excitement when CMS announced the ACCESS program. Finally, a way for digital health companies to make their mark on Medicare! A program that pays only if patients get better! Bu…
    Endpoints · 18d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
    Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
    STAT · 18d ago↗ source
  • How digital health companies are planning to conquer CMS ACCESS
    A new Medicare experiment to manage seniors’ chronic diseases will pay some digital health companies only about as much in a year as they might earn for a couple of patient visits from commercial i…
    Endpoints · 18d ago↗ source